The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant therapy versus upfront surgery for pancreatic adenocarcinoma: A propensity score matched analysis of short-term outcomes.
 
Gyulnara G. Kasumova
No Relationships to Disclose
 
Susanna W.L. de Geus
No Relationships to Disclose
 
Omidreza Tabatabaie
No Relationships to Disclose
 
Ayotunde B. Fadayomi
No Relationships to Disclose
 
Rebecca A. Miksad
Consulting or Advisory Role - 2nd.MD; Acceleron Pharma; Advanced Medical; Advanced Medical (I); Grand Rounds; Onyx; OptumInsight
Research Funding - Acceleron Pharma (Inst); ArQule (Inst); Bayer/Onyx (Inst); Daiichi Sankyo (Inst); Eisai; Genentech (Inst); Newlink Genetics (Inst)
 
Sing Chau Ng
No Relationships to Disclose
 
Arthur J. Moser
No Relationships to Disclose
 
Manuel M. Hidalgo
No Relationships to Disclose
 
Jennifer F. Tseng
Consulting or Advisory Role - Aegerion (I); Amgen (I); AstraZeneca (I); Bristol-Myers Squibb (I); Cubist (I); Daiichi Sankyo/Lilly (I); GlaxoSmithKline (I); Intarcia Therapeutics (I); Merck (I); MyoKardia (I); Pfizer (I); Quest Diagnostics (I); Sanofi (I); Vertex (I); Zeus Oncology Fund (I)